Brazilian company Precisa Medicamentos has requested emergency use of the Covaxin vaccine from the country’s health regulator.
Precisa Medicamentos made the request at the behest of India’s Bharat Biotech.
Anvisa, Brazil’s health regulator, has said that Covaxin will be trialed in phase three of their clinical trial. The clinical trial is being carried out in partnership with Sao Paulo’s Albert Einstein hospital.
Covaxin is the first vaccine to be produced in India, and was just found to have no serious side effects according to a study published by medical journal The Lancet. The Lancet would go on further to say that the efficacy of the vaccine could not be confirmed until phase 3 of the clinical trials in complete.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.